Literature DB >> 25194107

BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions.

Jonathan B Wallach1, Petra Rietschel2, Shalom Kalnicki1, Jana L Fox3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 25194107     DOI： 10.1016/j.prro.2013.10.007

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN： 1879-8500


× No keyword cloud information.
  3 in total

Review 1.  Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies.

Authors:  Elizabeth Guimond; Chiaojung Jillian Tsai; Ali Hosni; Grainne O'Kane; Jonathan Yang; Aisling Barry
Journal:  Adv Radiat Oncol       Date:  2022-07-14

Review 2.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

Review 3.  Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.

Authors:  Fleta N Bray; Brian J Simmons; Aaron H Wolfson; Keyvan Nouri
Journal:  Dermatol Ther (Heidelb)       Date:  2016-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.